oliver.stula@baselarea.swiss, Author at BaseLaunch

Gibela Publishes New Findings on CNNM4 in Metabolic Disease

Basel, Switzerland - 14 November 2025, Gibela Therapeutics GmbH (“Gibela”), the Basel-based Biotech focusing on the treatment of liver diseases using siRNA technology to target…

oliver.stula@baselarea.swiss14.11.2025

All Interviews

Deals, Mergers & Acquisitions: How to sell your company

Bringing a therapeutic innovation to market requires more than great science—it also demands long-term strategic thinking about funding, ownership, IP, future partnerships, and potential exit…

oliver.stula@baselarea.swiss28.10.2025

Portfolio news

Tolremo Announces Positive TT125-802 Results at ESMO 2025

Basel, Switzerland - October 17, 2025, TOLREMO therapeutics AG (TOLREMO) today announced encouraging clinical data from 34 patients with advanced solid tumors treated with TT125-802…

oliver.stula@baselarea.swiss20.10.2025

Portfolio news

Alentis appoints Dr. Mark Pruzanski as CEO

Basel, Switzerland – Oct 15, 2025, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology…

oliver.stula@baselarea.swiss16.10.2025

All

How Novo Nordisk partners with academia, biotech companies and beyond

How Novo Nordisk partners with academia, biotech companies and beyond Novo Nordisk began with a one-dollar insulin license. Today, it’s a global giant fighting more…

oliver.stula@baselarea.swiss26.09.2025

All Portfolio news

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

Basel, Switzerland - September 24, 2025, Synendos Therapeutics (“Synendos”), the clinical-stage biotech company developing breakthrough therapies for neuropsychiatric disorders, announced today topline results for its…

oliver.stula@baselarea.swiss24.09.2025

Portfolio news

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Basel, Switzerland – September 23, 2025 – metaLead Therapeutics AG (“metaLead”) announces the appointment of David Urech, PhD, Founder and former Chief Executive Officer of…

oliver.stula@baselarea.swiss23.09.2025

Portfolio news

Gibela publishes groundbreaking research in Hepatology

We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal. The company is…

oliver.stula@baselarea.swiss14.08.2025

All Portfolio news

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

Basel, Switzerland – Synendos Therapeutics, the clinical-stage biotechnology company developing breakthrough therapies for neuropsychiatric disorders, announced the appointment of Dr. George Garibaldi as Chief Medical…

oliver.stula@baselarea.swiss12.08.2025

Portfolio news

We welcome BioDuro as our new domain partner

We’re excited to share our new partnership with BioDuro, a trusted CRDMO with a 29-year proven track record and strong reputation for delivering high-quality, end-to-end…

oliver.stula@baselarea.swiss25.07.2025

oliver.stula@baselarea.swiss

Gibela Publishes New Findings on CNNM4 in Metabolic Disease

Deals, Mergers & Acquisitions: How to sell your company

Tolremo Announces Positive TT125-802 Results at ESMO 2025

Alentis appoints Dr. Mark Pruzanski as CEO

How Novo Nordisk partners with academia, biotech companies and beyond

Synendos Reports Positive Phase 1 Results for SYT-510, Preparing for Phase 2

metaLead Therapeutics Appoints David Urech as Member of the Board of Directors

Gibela publishes groundbreaking research in Hepatology

Synendos Appoints Dr. George Garibaldi as Chief Medical Officer

We welcome BioDuro as our new domain partner

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us